Literature DB >> 28342822

Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.

Cesar Sepúlveda1, Iván Palomo2, Eduardo Fuentes3.   

Abstract

Beyond its function in hemostasis, platelets activation has an important role in cardiovascular diseases (CVD) development. There are different clinical conditions that can mediate abnormal platelet activation and favors pathological thrombosis and CVD. These include Hypertension, diabetes and dyslipidemia, all risks factors from CVD development. Different drugs employed in the handled of these conditions have showed decreases platelet activation and related markers. This effect is in part by improved the base condition; however someone of these drugs can modulate platelet targets. We discuss about underlying mechanisms and the possible implications in the treatment of CVD.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Antiplatelet; Cardiovascular diseases; Diabetes; Drugs; Hypertension

Mesh:

Substances:

Year:  2017        PMID: 28342822     DOI: 10.1016/j.vph.2017.03.004

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  4 in total

1.  Iso-Osmolar Iodixanol Induces Less Increase in Circulating Endothelial Microparticles In Vivo and Less Endothelial Apoptosis In Vitro Compared with Low-Osmolar Iohexol.

Authors:  Beijian Zhang; Yi Zhang; Bo Liu; Lu Fang; Yigang Li; Shu Meng
Journal:  Contrast Media Mol Imaging       Date:  2018-04-10       Impact factor: 3.161

Review 2.  Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis.

Authors:  Milijana Janjusevic; Alessandra Lucia Fluca; Giulia Gagno; Alessandro Pierri; Laura Padoan; Annamaria Sorrentino; Antonio Paolo Beltrami; Gianfranco Sinagra; Aneta Aleksova
Journal:  Int J Mol Sci       Date:  2022-02-20       Impact factor: 5.923

3.  Aloe Emodin Reduces Cardiac Inflammation Induced by a High-Fat Diet through the TLR4 Signaling Pathway.

Authors:  Yingfu Chen; Burong Feng; Ye Yuan; Juan Hu; Wei Zhao; Huiwei Jiang; Wen Li; Ziyi Fan; Zhimin Du
Journal:  Mediators Inflamm       Date:  2020-02-05       Impact factor: 4.711

4.  Prior Use of Medication for Primary Prevention in Patients with Coronary Syndrome.

Authors:  Andrés Gaviria-Mendoza; Julián Andrés Zapata-Carmona; Andrés Alirio Restrepo-Bastidas; Carmen Luisa Betancur-Pulgarín; Jorge Enrique Machado-Alba
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.